The company develops AI-driven diagnostic solutions for haematology to automate and improve the accuracy of blood and bone marrow analysis.
Cancilico has raised €2.5M across 1 funding round from 4 investors, most recently a Seed round in Jan 2026. Based in Dresden, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-01-20 | Seed | €2.5M |
| GEDAD GmbH,High-Tech Gründerfonds (HTGF),ROI Verwaltungsgesellschaft,TGFS - Technologiegründerfonds Sachsen |
| View deal → |
